Barrett's esophagus: a comprehensive and contemporary review for pathologists
BV Naini, RF Souza, RD Odze - The American journal of surgical …, 2016 - journals.lww.com
This review provides a summary of our current understanding of, and the controversies
surrounding, the diagnosis, pathogenesis, histopathology, and molecular biology of Barrett's …
surrounding, the diagnosis, pathogenesis, histopathology, and molecular biology of Barrett's …
BOB CAT: a large-scale review and Delphi consensus for management of Barrett's esophagus with no dysplasia, indefinite for, or low-grade dysplasia
OBJECTIVES: Barrett's esophagus (BE) is a common premalignant lesion for which
surveillance is recommended. This strategy is limited by considerable variations in clinical …
surveillance is recommended. This strategy is limited by considerable variations in clinical …
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus
These guidelines provide a practical and evidence-based resource for the management of
patients with Barrett's oesophagus and related early neoplasia. The Appraisal of Guidelines …
patients with Barrett's oesophagus and related early neoplasia. The Appraisal of Guidelines …
Detection of mutations in Barrett's esophagus before progression to high-grade dysplasia or adenocarcinoma
MD Stachler, ND Camarda, C Deitrick, A Kim… - Gastroenterology, 2018 - Elsevier
Background & Aims Barrett's esophagus (BE) is the greatest risk factor for esophageal
adenocarcinoma (EAC), but only a small proportion of patients with BE develop cancer …
adenocarcinoma (EAC), but only a small proportion of patients with BE develop cancer …
[HTML][HTML] Abnormal TP53 predicts risk of progression in patients with Barrett's esophagus regardless of a diagnosis of dysplasia
M Redston, A Noffsinger, A Kim, FG Akarca, M Rara… - Gastroenterology, 2022 - Elsevier
Background and Aims Barrett's esophagus (BE) is the precursor to esophageal
adenocarcinoma. A major challenge is identifying the small group with BE who will progress …
adenocarcinoma. A major challenge is identifying the small group with BE who will progress …
Diagnostic and prognostic molecular biomarkers for prostate cancer
G Kristiansen - Histopathology, 2012 - Wiley Online Library
Kristiansen G (2012) Histopathology 60, 125–141 Diagnostic and prognostic molecular
biomarkers for prostate cancer Prostate cancer is the most common malignant tumour in …
biomarkers for prostate cancer Prostate cancer is the most common malignant tumour in …
Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis
R Krishnamoorthi, BP Mohan, M Jayaraj… - Gastrointestinal …, 2020 - Elsevier
Background and Aims Risk of progression in Barrett's esophagus (BE) with low-grade
dysplasia (LGD) and high-grade dysplasia (HGD) has been established. However, the …
dysplasia (LGD) and high-grade dysplasia (HGD) has been established. However, the …
Histopathologist features predictive of diagnostic concordance at expert level among a large international sample of pathologists diagnosing Barrett's dysplasia using …
MJ van der Wel, HG Coleman, JJ Bergman, M Jansen… - Gut, 2020 - gut.bmj.com
Objective Guidelines mandate expert pathology review of Barrett's oesophagus (BO)
biopsies that reveal dysplasia, but there are no evidence-based standards to corroborate …
biopsies that reveal dysplasia, but there are no evidence-based standards to corroborate …
[HTML][HTML] Machine learning for grading and prognosis of esophageal dysplasia using mass spectrometry and histological imaging
M Beuque, M Martin-Lorenzo, B Balluff… - Computers in biology …, 2021 - Elsevier
Background Barrett's esophagus (BE) is a precursor lesion of esophageal adenocarcinoma
and may progress from non-dysplastic through low-grade dysplasia (LGD) to high-grade …
and may progress from non-dysplastic through low-grade dysplasia (LGD) to high-grade …